CancerDrs

Brain Cancer clinical trials

300 actively recruiting brain cancer trials in the United States. Primary brain tumors including glioblastoma multiforme (GBM), lower-grade gliomas, and other CNS malignancies.

Data from ClinicalTrials.gov · last refreshed · Brain Cancer stats on SEER

70
Phase 1
91
Phase 2
14
Phase 3
5
Phase 4
120
Other

Brain Cancer by the numbers (U.S.)

24,820
Estimated new cases (2025)
18,330
Estimated deaths (2025)
33%
5-year relative survival
61
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse brain cancer trials by state

Top trials by phase + site coverage

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Locations:
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Alaska Breast Care and Surgery LLC — Anchorage, Alaska
  • Alaska Oncology and Hematology LLC — Anchorage, Alaska

+ 574 more sites in the U.S.

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas

+ 259 more sites in the U.S.

Phase 3 Recruiting Network

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …

Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • USA Health Strada Patient Care Center — Mobile, Alabama
  • Phoenix Childrens Hospital — Phoenix, Arizona

+ 101 more sites in the U.S.

Phase 3 Recruiting Academic/Other

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Locations:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California

+ 79 more sites in the U.S.

Phase 3 Recruiting Network

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Locations:
  • University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
  • City of Hope Corona — Corona, California

+ 70 more sites in the U.S.

Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Locations:
  • Banner MD Anderson Cancer Center — Phoenix, Arizona
  • Barrow Neurological Institute — Phoenix, Arizona
  • Phoenix Childrens Hospital — Phoenix, Arizona

+ 64 more sites in the U.S.

Phase 3 Recruiting Industry

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …

Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Locations:
  • University of Alabama — Birmingham, Alabama
  • Mayo Clinic - Arizona — Phoenix, Arizona
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona

+ 39 more sites in the U.S.

Phase 3 Recruiting Industry

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…

Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Locations:
  • Mayo Clinic Hospital — Phoenix, Arizona
  • University of Southern California — Los Angeles, California
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California

+ 33 more sites in the U.S.

Phase 3 Recruiting Industry

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…

Sponsor: InSightec
NCT ID: NCT05317858
Locations:
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California
  • Miami Cancer Institute at Baptist Health — Miami, Florida

+ 6 more sites in the U.S.

Phase 3 Recruiting Industry

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…

Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Locations:
  • HonorHealth Scottsdale Osborn Medical Center — Scottsdale, Arizona
  • Jersey Shore University Medical Center | Hackensack — Neptune City, New Jersey
  • Westchester Medical Center — Valhalla, New York

+ 3 more sites in the U.S.

Phase 3 Recruiting Academic/Other

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…

Sponsor: Mayo Clinic
NCT ID: NCT03750227
Locations:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
  • Mayo Clinic in Florida — Jacksonville, Florida
  • National Institutes of Neurological Disorders and Stroke, NIH — Bethesda, Maryland

+ 1 more site in the U.S.

Phase 3 Recruiting Academic/Other

18F-FLUC PET/MR in Patients With Brain Mets

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomogr…

Sponsor: University of Wisconsin, Madison
NCT ID: NCT06159335
Locations:
  • University of Wisconsin — Madison, Wisconsin

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27